DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, has published a study in the peer-reviewed “Frontiers in Endocrinology” journal. According to the announcement, the study provides an overview of new research that confirms the benefit of Dario’s integrated, data-driven approach to health and chronic-condition management. The study examined retrospective data from 989 users who regularly tracked their steps levels and blood glucose (“BG”) levels for 12 months using Dario’s cardiometabolic solution. Data gathered demonstrated the effectiveness of Dario’s cardiometabolic solution for individuals living with diabetes or prediabetes and depression. The research was conducted in partnership with Integrative Pain Laboratory, the School of Public Health at the University of Haifa , Israel.
“Dario is uniquely positioned to help shed light on the relationship between physical and mental health, thanks to the rich volume of data we are able to gather and analyze for insights that benefit our members and our partners,” said Dario chief medical officer Omar Manejwala, MD, in the press release. “This new research exemplifies the advantages of our data-driven approach to digital health and supports the value of our integrated approach to help employers and health plans to tackle costly and frequently comorbid conditions.”
To view the full press release, visit https://ibn.fm/YZydT
About DarioHealth Corp.
DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic-condition, digital-therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
